C lostridium difficile infection (CDI) represents an important public health problem in both acute-and chronic-care facilities (1) . CDI is involved in a significant proportion of cases of antibioticinduced diarrhea and can lead to severe outcomes such as pseudomembranous colitis and toxic megacolon (2) . The occurrence of CDI has increased in the past two decades, with localized outbreaks of increased severity (especially in North America [including Quebec]) occurring in conjunction with the emergence of the more virulent NAP1/ B1/027 strain (3) (4) (5) (6) (7) (8) . During an outbreak in Quebec in 2004, Loo et al (3) estimated the incidence of nosocomial CDI to be 22.5 cases per 1000 admissions and the attributable mortality to be 6.9% per case. The Canadian Nosocomial Infection Surveillance Program Study (9) reported an incidence of 4.6 health care-associated CDI cases per 1000 hospital admissions and an attributable mortality rate of 5.7% per case across Canada in early 2005. Corresponding figures were significantly higher for Quebec, with 12.8 cases per 1000 admissions and a reported mortality rate of 14.9% (9) .
The rising incidence of CDI and the increasing proportion of more severe cases in Quebec during the period from 1991 to 2004 (10, 11) led to an increased economic burden associated with this disease. Nevertheless, data regarding the economic burden of CDI in a Canadian context are scarce (1, 12) . In 2002, a Canadian cross-sectional study reported a minimum cost (antibiotic treatment and hospital stay only) of $128,200 per hospital for an average of 10 readmissions for nosocomial C difficile-associated diarrhea (13) . Based on a systematic literature review, the annual attributable health care costs of CDI in the United States were estimated to range from $433 million to $797 million per year (in 2008 $USD) (12) . Similar data are not available for Canada.
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According to current clinical practice guidelines for CDI in adults, metronidazole is the preferred treatment for mild to moderate CDI, whereas vancomycin is indicated for severe disease (14) (15) (16) . A combination of vancomycin and metronidazole administered orally and intravenously, respectively, is the preferred treatment for severe, complicated CDI (15, 16) . Recurrence of infection from the original strain (relapse) or from another strain (reinfection) remains an important issue, with 20% to 35% of patients with a first episode of C difficileassociated diarrhea experiencing at least one recurrence after the end of the initial standard therapy (vancomycin or metronidazole) (17, 18) . Guidelines recommend the same regimen for the treatment of a first recurrence as for the initial episode (14) (15) (16) .
In a recent review of the comparative efficacy of C difficile treatments, Drekonja et al (19) concluded that metronidazole, vancomycin and the new macrocyclic antibiotic fidaxomicin are similarly effective for initial cure of CDI in patients with diseases of variable severity. The review included the recent noninferiority trial conducted in Canada and the United States comparing fidaxomicin with vancomycin in CDI patients, which showed similar initial clinical cure rates (88.2% versus 85.8%, respectively) in the modified intention-to-treat population (n=596) but fewer recurrences for fidaxomicin compared with vancomycin overall (15.4% versus 25.3%, respectively) and for patients infected with non-NAP1/B1/027 strains (10.3% versus 28.1%, respectively) (20) . A second noninferiority clinical trial conducted in Europe and North America comparing fidaxomicin and vancomycin for treatment of patients with CDI was published after this review and reported similar results in the modified intention-to-treat population (n=509) (21) . A meta-analysis of the two trials recently reported that fidaxomicin reduced by 40% a composite end-point of persistent diarrhea, recurrence or death during a 40-day follow-up (22) . Although leading to fewer recurrences, fidaxomicin treatment is more expensive than treatment with vancomycin (19) and its cost utility from the perspective of a third-party payer in the United States has been recently estimated to be US$67,576 per quality-adjusted life year (23) .
The significant burden of CDI and the availability of a new treatment prompted us to evaluate the clinical and economic consequences of using vancomycin compared with fidaxomicin in the treatment of patients with CDI in the Canadian context from the perspective of the publicly funded health care system.
METHODS

Model design
A decision-tree model was developed in Excel 2007 (Microsoft Corporation, USA) to compare vancomycin and fidaxomicin for the treatment of patients with severe CDI (Figure 1 ). The treatment regimens compared were vancomycin (Vancocin) 125 mg every 6 h for 10 days and fidaxomicin (Dificid; Optimer Pharmaceuticals Canada Inc, Canada) 200 mg every 12 h for 10 days, as used in the comparative clinical trials (20, 21) . Model transition probabilities are presented in Table 1 . It was assumed that initial cure rates were identical in the two treatment arms because of the noninferiority reported in the trials (20, 21) . After initial cure, the analysis included only the first recurrent episode of CDI, for which comparative rates following vancomycin and fidaxomicin in severe CDI patients were available (20, 21) . Transition probabilities of initial cure and recurrence rates were calculated as the weighted average of rates from the two Table 1 . For recurrence rates, 95% CIs were calculated using the following equation:
in which p is the weighted average recurrence rate and n is the total number of observations (patients).
The incremental cost per recurrence avoided was used as the measure of cost effectiveness. Recurrence was defined as reappearance of >3 diarrheal stools in 24 h within 28 days after the final dose of study medication; C difficile toxin A or B, or both, in stool samples; and a need for retreatment for CDI (20, 21) . It was assumed that the episode of recurrence was treated using the same medication regimen as the initial episode, as recommended in clinical guidelines (14) (15) (16) . The proportion of patients hospitalized for recurrence of CDI was derived from two studies. One study reported that 62% of patients experiencing a first episode of CDI were hospitalized within 60 days of recurrence (without providing the reason for hospitalization) (24) . A second study reported that, among patients who were rehospitalized after an initial episode of CDI, 31% received a primary diagnosis of CDI (25) . These two proportions were multiplied to estimate that 19.3% of patients were hospitalized with recurrence of CDI. The time horizon of the analysis was approximately two months after onset of the initial episode, which corresponds to the time over which the occurrence of the first recurrence was followed in the two clinical trials (20, 21) .
Patient population
The target population of the model were patients with severe CDI as defined by clinical guidelines (ie, patients with a white blood cell count 15×10 9 cells/L or a serum creatinine level ≥1.5 times the premorbid level [15] ). This definition approximates the population defined as severe in the clinical trials comparing fidaxomicin with vancomycin (Louie et al [20] and Cornely et al [21] ), which included patients with ≥10 unformed bowel movements per day or with body temperature >38.5°C, respectively, as additional possible inclusion criteria (20, 21) .
Resource utilization and costs
In accordance with the health care system perspective of the present analysis, the model included direct treatment costs, ie, study medication, physician services and hospitalization. Resource utilization and unit costs are listed in Tables 2 and 3 , respectively. Resource utilization was based on the Louie et al (20) and Cornely et al (21) studies and on published Canadian sources (7, 24, 26) . Medication was assumed to be the same for the recurrent and initial episodes. The proportion of inpatients in the population entering the model was the same for both the fidaxomicin and vancomycin treatment arms, similar to the two clinical trials, and was estimated as the average of proportions reported in these trials (20, 21) . It was assumed that one medical consultation and two additional assessments by a gastroenterologist or an infectious disease specialist were required for each patient hospitalized for CDI. The proportion of patients who underwent a colectomy during the initial episode of CDI was derived from a study involving 266 patients in Quebec with severe CDI defined by either leukocyte count or creatinine level (7) . The proportion of patients who had a colectomy during the recurrent episode was derived from the number of colectomies among the patients (n=463) who had a first recurrence of C difficile-associated disease in another study from the same research group (24) .
The fidaxomicin acquisition cost was based on the value cited in the Common Drug Review of fidaxomicin by the Canadian Agency for Drugs and Technologies in Health (27) . The costs of inpatient and outpatient physician consultations and assessments were obtained from the Ontario Schedule for Physician Services (28) , and the cost for colectomy was obtained from a report of the Canadian Agency for Drugs and Technologies in Health (26) . The hospital cost of an acute stay for enterocolitis (referred as the most responsible diagnosis in this database) was obtained from the Ontario Case Costing Initiative (29) .
Subgroup analysis: patients with recurrent CDI
An alternative analysis targeting patients who present with recurrent CDI was also performed. This patient population corresponds to the subgroup of patients in the two head-to-head clinical trials who, at baseline, presented with a first recurrent episode of CDI and were then randomly assigned to fidaxomicin or vancomycin (30) (treatment of the initial episode of CDI in these patients had consisted of metronidazole [52%], vancomycin [18%], combinations of these two [13.3%] or no medication [17%]) (30) . In this subgroup of patients, the reported recurrence rates after successful initial treatment with fidaxomicin or vancomycin, thus, represent rates of second recurrence (30) . The reported rates were not delineated by initial disease severity (30) .
Sensitivity analyses
The impact of the uncertainty of model input parameters on the incremental cost per recurrence avoided was assessed using deterministic sensitivity analyses. The varied parameters were the recurrence rate after fidaxomicin treatment, the proportion of patients hospitalized for CDI recurrence, hospitalization costs, the number of additional in-hospital assessments by a specialist and medication treatment duration. Lower and upper limits of the 95% CI of the weighted average of recurrence rates after fidaxomicin treatment from the two clinical trials were used as lower and higher bound values for the first sensitivity analysis. The lower bound value for the proportion of patients hospitalized for recurrence was the proportion of patients with complications during recurrence (11%) as reported by Pépin et al (24) . This value represents −43% of the base case value. The higher bound value was +43% of the base case value. The hospitalization cost was varied between the Ontario Case Costing Initiative cost for typical cases (n=557) and the cost for all cases regardless of case mix group (n=711). The number of additional inhospital assessments by a specialist was varied between one and three. The medication treatment duration was varied by four days around the base case value (10 days), because clinical guidelines recommend up to 14 days of treatment (14, 15) .
Analysis according to strain type
Because recurrence rates were significantly lower with fidaxomicin compared with vancomycin only for patients infected with non-NAP1/ B1/027 strains and not for patients with NAP1/B1/027 strains (20, 21) , the impact of varying the proportion of patients infected with NAP1/ B1/027 was investigated by varying this proportion from 0% to 100% in a linear interpolation of averaged data from the two clinical trials.
RESULTS
Base case results
Compared with vancomycin, treatment of 1000 patients with severe CDI with fidaxomicin led to 137 fewer recurrences and 26 fewer patients hospitalized for recurrence ( Table 4 ). The use of fidaxomicin increased the cost of initial treatment by $1.81 million due to higher 
Subgroup analysis
When only the subgroup of patients with recurrent CDI was taken into account, according to the pooled report of the two clinical studies (30), treatment of 1000 patients who experienced a first recurrence with fidaxomicin instead of vancomycin led to 113 fewer second recurrences and 22 fewer patients hospitalized for a second recurrence ( Table 5 ). The initial incremental cost of treating 1000 patients with recurrent CDI with fidaxomicin rather than vancomycin was the same as in the base case ($1.99 million); the incremental cost of treating second recurrences was $69,863 per 1000 patients. Collectively, this resulted in a total incremental cost for fidaxomicin versus vancomycin of $2.06 million per 1000 patients with a first recurrence (had already experienced a CDI episode) or $18,190 per second recurrence avoided. When only the costs of the initial treatment of the first recurrence were taken into account (ie, $1.99 million per 1000 patients), disregarding treatment of second recurrences, the incremental cost per second recurrence avoided was $17,574 (data not shown). If a first recurrent episode is treated with vancomycin and fidaxomycin is only reserved for a second recurrence, the total incremental cost of this strategy compared with continuing vancomycin treatment per 1000 patients with recurrent CDI would be reduced to $0.6 million (data not shown).
Sensitivity analyses
The model was sensitive to the recurrence rate in the fidaxomicin arm. An increase of this parameter to the upper limit of its 95% CI (ie, to 0.167) reduced recurrences avoided to 94 per 1000 patients initially treated with fidaxomicin versus vancomycin, while increasing the incremental total cost to $2.0 million and the incremental total cost per recurrence avoided to $21,330 (+62% from base case). On the other hand, a decrease of the fidaxomicin recurrence rate to the lower limit of its 95% CI (ie, to 0.062) resulted in 180 recurrences avoided at an incremental total cost of $1.6 million and $8,946 per recurrence avoided (−32% of base case) ( Figure 2) . The model was also sensitive to the duration of treatment; an extension from 10 to 14 days led to an increase of incremental cost per recurrence avoided by fidaxomicin compared with vancomycin to $19,472 while a shorter treatment (six days) resulted in a decrease to $6,932 ( Figure 2) . The model was slightly sensitive (±8%) to variations in the proportion of patients hospitalized for recurrence, which was varied ±43% around the base case value (Figure 2) . The model was also slightly sensitive to variations in hospitalization costs, with an increase of incremental cost per recurrence avoided by fidaxomicin compared with vancomycin to $13,797 (+5%) for the lower bound of costs, and a decrease to $12,650 (−4%) for the higher bound. The model was marginally sensitive (±0.1%) to the number (one to three) of additional in-hospital assessments by a gastroenterologist or an infectious disease specialist.
Impact of the proportion of CDI cases caused by the NAP1/ B1/027 strain
When analyzing the combined clinical data according to strain type, recurrence rates between treatments showed a statistically significant difference for patients infected with non-NAP1/B1/027 strains (fidaxomicin: 0.097 versus vancomycin: 0.278; P<0.0001) but not for those infected with NAP1/B1/027 strains (fidaxomicin: 0.248 versus vancomycin: 0.282; P=0.56). Figure 3 shows the impact of the proportion of cases caused by the NAP1/B1/027 strain on the number of recurrent cases avoided by fidaxomicin versus vancomycin per 1000 patients entering the model (panel A), and the incremental cost per recurrence avoided (panel B) using weighted average recurrence rates from the two clinical trials (20, 21) . In this figure, the solid lines show the results obtained using the mean estimates for all rates, whereas the dotted and dashed lines show the ranges obtained by varying the recurrence rate for fidaxomicin-treated patients infected with NAP1/B1/027 strains from lower and upper bounds, respectively, of its 95% CI (ie, 0.168 to 0.327 [ Table 1] ). If among 1000 CDI patients all cases were caused by non-NAP1/ B1/027 strains, 165 recurrences would be avoided with fidaxomicin versus vancomycin and the total incremental cost per recurrence avoided would reach a minimum of $10,504. As the proportion of patients infected with NAP1/B1/027 strains increases, fidaxomicin becomes progressively less cost effective. If, among 1000 patients, all cases were caused by NAP1/B1/027 strains, the mean number of recurrences avoided would reach a minimum of 28 and the mean incremental cost per recurrence avoided a maximum of $83,295.
As the dotted and dashed lines show, the above-mentioned results were highly sensitive to the differential in recurrence rates among NAP1/B1/027-infected patients, with increasing uncertainty with a rising proportion of NAP1/B1/027-infected patients. In the case of a patient population with 100% of cases caused by NAP1/B1/027 strains, the number of recurrences avoided when using fidaxomicn versus vancomycin ranged between 93 and −37, and the corresponding incremental cost per recurrence avoided between $21,798 and an additional cost of $71,151 per additional case of recurrence. Similar results were obtained when varying the recurrence rate among NAP1/B1/027infected, vancomycin-treated patients across its 95% CI, while keeping the corresponding fidaxomicin rate constant (data not shown).
DISCUSSION
In the past 15 years, CDI has become more challenging to the health care system due to increased incidence and severity. C difficile remains the most important cause of health care-associated diarrhea and can lead to severe outcomes including pseudomembranous colitis, toxic megacolon and death (2) . Vancomycin is currently the treatment of choice for severe CDI (14, 15) . Fidaxomicin, recently approved by Health Canada for the treatment of patients with CDI, was shown to be noninferior to vancomycin for clinical cure and was associated with significantly lower rates of recurrence overall and among the subpopulation of patients with CDI caused by non-NAP1/B1/027 strains (20, 21) . For patients with severe CDI, the present study revealed an incremental cost of $13,202 per recurrence case avoided by fidaxomicin compared with vancomycin from the perspective of the Canadian public health care system. Among patients presenting with a first recurrent episode of CDI, the incremental cost of a second recurrence avoided was $18,190 . The incremental cost-effectiveness ratio was sensitive to the duration of treatment, the recurrence rate and the proportion of CDI cases caused by the NAP1/B1/027 strain.
Although clinical guidelines for CDI in adults recommend 10 days of treatment, it is recognized that some patients may respond slowly to treatment and may require a longer course (eg, 14 days) (15) . In addition, many clinicians prolong the treatment of CDI to avoid recurrence, especially in patients receiving other antimicrobial agents (15) . In the present study, an increase in the duration of treatment from 10 days to 14 days led to a 47% increase (from $13,202 to $19,472) in the incremental cost per recurrence avoided by fidaxomicin compared with vancomycin.
Varying the recurrence rate among patients with severe CDI treated with fidaxomicin across its 95% CI, as derived from the two clinical studies, also strongly impacted model outputs, which, as a consequence, varied from $8,946 to $21,330 per recurrence case avoided.
In the analysis according to strain type, the proportion of CDI cases caused by the hypervirulent strain NAP1/B1/027 had a major impact on the comparative effectiveness and cost effectiveness of fidaxomicin versus vancomycin because, in contrast to non-NAP1/ B1/027 strains, fidaxomicin treatment did not lead to statistically significantly fewer recurrences in patients infected with the NAP1/ B1/027 strain (20, 21) . The NAP1 strain is postulated to be more virulent than other strains because of a deletion in the tcdC gene leading to increased toxin A and B production (31) . An association between NAP1/B1/027 and severe clinical outcomes (32, 33) as well as higher risk of infection rather than colonization (34) in nonepidemic settings was observed in Canada but not in the United States (35) and England (5), suggesting the involvement of uninvestigated local factors. The proportion of patients infected with NAP1 strains appears to be quite variable in time and location. During the six-month period from November 2004 to April 2005, it was reported to range from 7% in Manitoba and Saskatchewan to 76% in Quebec, with an average of 31% across nine Canadian provinces (33) . Across other Canadian studies (4, 31, 32, 36) , the proportion of patients infected with NAP1 strains ranged from 26% in Ontario in 2004 to 2006 (75% of which belonged to the NAP1 ribotype 027 associated with outbreaks) (36) to 75% during the 2003 to 2004 outbreak in the Montreal area (4) The two most recent studies reported a NAP1 proportion of 63% across six hospitals in Quebec and Ontario in 2006 to 2007 (34) and 53% during an outbreak in Ontario in 2008 to 2009 (8) . Assuming that 53% of cases in a patient population are caused by the NAP1/B1/027 strain (the lowest value reported in Canadian outbreaks), the model predicts 89 fewer recurrences per 1000 patients treated with fidaxomicin rather than vancomycin at an incremental cost of $23,258 per recurrence avoided (an increase of 76% from the base case).
The results of the present study should be considered in light of several limitations. Due to unavailability of data regarding the risk of subsequent recurrent episodes and on outcomes of treatment of recurrent episodes with fidaxomicin versus vancomycin, the model took into account the first recurrent episode in patients with severe disease (base case) or the second recurrent episode (subgroup analysis) in the 28 days following treatment of the initial episode or the first recurrence of CDI, respectively. An initial CDI episode can be followed by several recurrent episodes (37, 38) , which would reduce the incremental cost per patient with recurrent disease avoided. In addition, avoidance of such CDI recurrences should reduce the rate of person-to-person transmission, which was not captured by our model.
Figure 3) Relationship of number of recurrences avoided (A) and of cost per recurrence avoided (B) by fidaxomicin versus vancomycin with the proportion of cases caused by NAP1/B1/027 strains in 1000 patients with Clostridium difficile infection. Dotted and dashed lines show lower and upper bounds, respectively, of the 95% CI for recurrence rate in fidaxomicin-treated patients infected with NAP1/B1/027 strains
Another limitation was that the proportion of patients hospitalized for a first recurrence in the model (19.3%) was indirectly inferred from two observations: 62% of patients experiencing a first episode of CDI were hospitalized (for any reason) within 60 days of a first recurrence (24) ; and 31% of rehospitalized patients received a primary diagnosis of CDI (25) . Although fidaxomicin treatment was shown to lead to fewer recurrences compared with vancomycin (20) , sensitivity analyses around this value (±43%) had a minor impact on the incremental cost per recurrence avoided. Also, it was assumed in the model that the first recurrence was of same length and severity compared with the initial episode of CDI. However, in a study enrolling >200 patients experiencing recurrent C difficile-associated disease, the first recurrence compared with the initial episode was associated with a shorter duration of diarrhea and less severity of other clinical symptoms such as fever and abdominal pain (38) . Thus, according to these observations, the cost of first recurrence may be lower than that of the initial episode, implying that the incremental cost per recurrence avoided with fidaxomicin versus vancomycin may be underestimated.
Uncertainty regarding the recurrence rate differential between fidaxomicin and vancomycin for patients with severe disease, the current target population for vancomycin treatment, and especially for patients infected with the hypervirulent NAP1/B1/027 strain, for whom no statistically significant difference was shown in both clinical trials, also limits the generalizability of the model results. It is important to realize that these recurrence rates were based on subpopulations of the two clinical trials: a total of 292 patients with severe disease and of 230 patients infected with the NAP1/B1/027 strain, who were not further delineated by disease severity. More clinical data, ideally involving Canadian patients with severe disease, would be needed to increase the precision of the recurrence rate estimates. Local data would be particularly important in light of the apparent impact of the strain type (NAP1/ B1/027 versus non-NAP1/B1/027) on the differential in recurrence rates between fidaxomycin and vancomycin and the importance of the NAP1/B1/027 strain in recent Canadian outbreaks. Also, more realworld data is needed to explore in more detail the health care resource implications of recurrent CDI and to identify which populations would benefit the most from the available treatment options.
CONCLUSION
The use of fidaxomicin compared with vancomycin is associated with a cost increase for the Canadian health care system. In patients with severe CDI as defined in clinical guidelines, the total incremental cost per recurrence avoided with fidaxomicin versus vancomycin ($13,202) is sensitive to the recurrence rate after fidaxomicin treatment and the duration of treatment. The proportion of cases caused by the NAP1/ B1/027 strain in patient populations with CDI also has a strong impact on the differential effectiveness and cost effectiveness of the two treatments.
